Riskpilot← Back to searchSign inGet full accessModus Therapeutics Holding AB
ABActiveOrg 5568519523Olof Palmes Gata 29 IvBusiness and other management consultancy activities · NACE 7020Est. 20112 employees
Revenue 2024
SEK 740K
0% vs 2023
EBITDA margin
-921.8%
+6% vs 2023
Equity ratio
—
Financial strength
Net profit 2024
SEK -15M
+1% vs 2023
| Revenue | SEK 740K | +0% |
| EBITDA | SEK -6,8M | +6% |
| Net profit | SEK -15M | +1% |
| Total assets | SEK 72,7M | -18% |
| Equity | — | — |
| Employees | 2 | — |
Legal name
Modus Therapeutics Holding AB
Org number
5568519523
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
6 maj 2011
Share capital
SEK 2 156 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska direkt eller indirekt bedriva forskning-, utveckling-, försäljning- och licensieringsverksamhet inom läkemedelsområdet och därmed förenliga tjänster.
Address
Olof Palmes Gata 29 Iv
Email
john.ohd@modustx.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 609 | 505 | 740 | 740 | 740 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −2 141 | −6 524 | −6 332 | −7 267 | −6 821 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | −2 141 | −6 524 | −6 332 | −7 267 | −6 821 |
| Net financials | 65 256 | −1 | −314 | −1 496 | 293 |
| Profit before tax | 63 115 | −31 725 | −24 546 | −15 187 | −6 528 |
| Tax | −0 | −0 | −0 | −0 | −8 440 |
| Net profit | 63 115 | −31 725 | −24 546 | −15 187 | −14 968 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 77 314 | 89 871 | 79 824 | 89 194 | 72 733 |
| Equity | 76 129 | 73 709 | 49 162 | 72 138 | — |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 185 | 16 162 | 30 662 | 17 055 | 15 563 |
| Total debt | 1 185 | 16 162 | 30 662 | 17 055 | 15 563 |
EBITDA margin
-921.8%
This company
15.8%
Market median
-5934% vs market
20202024
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20202024
Return on equity
-1496800000.0%
This company
18.4%
Market median
-8134782709% vs market
20202024
Net profit margin
-2022.7%
This company
8.1%
Market median
-25072% vs market
20202024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20202024
Debt / equity
72732999.00×
This company
0.62×
Market median
-11731128771% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JF Chief Executive Officer | Chief Executive Officer | 2022 |
LM Chief Auditor | Chief Auditor | 2023 |
| Former (2) | ||
EO Chief Auditor | Chief Auditor | 2020 – 2023 |
EK Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2024 | |
| Board of Directors | 2023 | |
| Former (4) | ||
| Chairman | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 66% | 66% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
KDventures AB
Modus Therapeutics Holding AB Board members of Modus Therapeutics Holding AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Oskar Wall | Chief Auditor | 0 companies |
| Ellen Kinson Donnelly | Chief Executive Officer | 0 companies |
| John Fredrik Öhd | Chief Executive Officer | 0 companies |
| Linn Maria Haslum Lindgren | Chief Auditor | 0 companies |
| Viktor Drvota | Chairman | 0 companies |
| Stig Løkke Pedersen | Chairman | 0 companies |
| Miroslav Reljanovic | Board of Directors | 0 companies |
| Johan Ulf Niclas Dighed | Board of Directors | 0 companies |
| Mårten Steen | Board of Directors | 0 companies |
| Torsten Rüdiger Goesch | Board of Directors | 0 companies |
| Ellen Kinson Donnelly | Board of Directors | 0 companies |